Bristol Myers Squibb is ending a phase 3 clinical trial of a combination treatment for metastatic colorectal cancer after an independent committee determined it was unlikely to produce meaningful results, the drugmaker said Dec. 15.
The trial was assessing the efficacy of a fixed-dose combination of nivolumab and relatlimab in patients with microsatellite stable metastatic colorectal cancer whose disease has progressed after one to four prior lines of therapy.
Bristol Myers Squibb noted the trial's cancellation was not due to safety concerns and said it will continue exploring the combination therapy as a potential treatment for other tumor types.
The drugmaker will also share data with investigators so they can determine next steps for patients currently enrolled in the trial.
Learn more here.